IDH1 (R132H)

    Neuropathology/Endocrine
    ZR7 Rabbit Monoclonal

    Zeta IDH1 (R132H) Antibody.  Zeta’s recombinant rabbit antibody recognizes IDH1 (R132H) but specifically binds to the IDH1-mutated protein but does not bind the wild-type IDH1 protein.  IDH1 (R132H) point mutations are frequently seen in grade II and III gliomas, and the IDH1 (R132H) point mutations are believed to constitute an early step in tumorigenesis. IDH1 (R132H) can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 (R132H) antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the IDH1 (R132H)-mutated peptide. The IDH1 antibody shows diffuse staining of the fibrillary tumor matrix

    Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists.  Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.

    Specifications
    Species Reactivity:Humans; others not tested
    Known Applications:Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
    Supplied As:Buffer with protein carrier and preservative
    Storage:Store at 2ºC to 8ºC
    Control:Infiltrating glioma
    Visualization:Nuclear
    Isotype:IgG
    Immunogen:Recombinant fragment of human IDH1 (exact sequence is proprietary)
    Ordering Information
    Classification IVD
    Catalogue Number Z2010RL
    Classification IVD
    Catalogue Number Z2010RL
    Package Inserts
    IFU-IDH1 (R132H) ZR7 - IVDL
    Regulatory Notice
    Product classification varies based on regulations of individual countries. Please contact your local distributor for more information. Products labeled as ASR or RUO in the US might be available as IVD or RUO in respective countries.
    SDS
    SDS